Analysis of Genomic Alterations in Metastases Moves Research Toward Personalized Approaches in RCC
April 11th 2022In an interview, Rana McKay, MD, discussed findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, further research in the field, and findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.
Cilta-cel Demonstrates Significant Advantage Over SOC in Triple-Class R/R Myeloma
December 13th 2021A CARTITUDE-1 meta-analysis data shows that ciltacabtagene autoleucel performs better than standard-of-care therapy in terms of survival and response rates in patients with triple-class relapsed/refractory multiple myeloma.